{"id":"834a5b23bb57","type":"article","url":"https://hartvaat.nl/2021/09/01/ace-remmer-plus-calciumantagonist-bij-zwarte-hypertensieve-patienten/","title":"ACE-remmer plus calciumantagonist bij zwarte hypertensieve patiënten","title_en":"Cardiovascular Benefits of Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Black Hypertensive Patients.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["ace-remmers","amlodipine","aprocitentan","baxdrostat","bloeddrukbehandeling","calciumantagonisten","cardiorenal-behandelstrategie","ezetimibe","figaro-dkd","lorundrostat","precision-trial","ramipril","ras-remmers","resistente-hypertensie","sacubitril-valsartan"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.121.17990","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.121.17990","authors":["Robert D Brook","Niko Kaciroti","Taylor Jamerson","Kenneth A Jamerson"],"significance":6,"published":"2021-09-01","source_date":"2021-09-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-diabetes/"],"congress":"","summary_en":"This analysis showed that combination ACE inhibitor plus calcium channel blocker therapy provides superior cardiovascular benefit in Black hypertensive patients, informing drug class selection in populations with different pharmacogenomic responses.","created":"2026-07-03T10:29:21Z","updated":"2026-07-03T18:38:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse naar de cardiovasculaire voordelen van combinatie ACE-remmer plus calciumantagonist bij zwarte hypertensieve patiënten.","abstract_original":""}